title: Which patients with hepatitis C develop liver complications?
abstract: To identify variables that are independent predictors of adverse outcomes in chronic hepatitis C, we analyzed a cohort of 455 patients followed for a median of 4.7 years. Associations were sought between demographic and behavioral factors, hepatitis C virus (HCV) genotype, liver histology and liver tests at entry, and development of liver complications, hepatocellular carcinoma (HCC), hepatic transplantation and liver-related death. Independent predictors were identified by multivariate analysis. The following were associated with a significantly higher rate of liver complications: age; birth in Asia, Europe, Mediterranean region, or Egypt; transmission by blood transfusion or sporadic cases; HCV genotypes 1b and 4 (compared with 1/1a); fibrosis stage 3 or 4 (cirrhosis); serum albumin; bilirubin; prothrombin time; and alpha-fetoprotein. However, the only independent predictors of liver-related complications were sporadic transmission (P <.001), advanced fibrosis (P =.004), and low albumin (P <.001). The corresponding independent risk factors for HCC were male gender (P =. 07), sporadic transmission (P <.001), and albumin (P <.001); bilirubin (P =.02) was an additional predictor of transplantation or liver-related death. It is concluded that only patients with advanced hepatic fibrosis or cirrhosis, are at risk of developing hepatic complications of chronic hepatitis C during 5-year follow-up. Among such patients, abnormalities in serum albumin, bilirubin, or prothrombin time indicate a high probability of complications. Patients without definite risk factors for HCV (sporadic cases) are at higher risk of complications, possibly because of interaction between older age, duration of infection, country of birth, and HCV genotypes 1b and 4.
authors.affiliation: Storr Liver Unit, University of Sydney at Westmead Hospital, Australia.
authors.forename: M H
authors.initials: MH
authors.lastname: Khan
authors.forename: G C
authors.initials: GC
authors.lastname: Farrell
authors.forename: K
authors.initials: K
authors.lastname: Byth
authors.forename: R
authors.initials: R
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Weltman
authors.forename: J
authors.initials: J
authors.lastname: George
authors.forename: D
authors.initials: D
authors.lastname: Samarasinghe
authors.forename: J
authors.initials: J
authors.lastname: Kench
authors.forename: S
authors.initials: S
authors.lastname: Kaba
authors.forename: E
authors.initials: E
authors.lastname: Crewe
authors.forename: C
authors.initials: C
authors.lastname: Liddle
mesh_terms: D000328:Adult; D000368:Aged; D000428:Alcohol Drinking; D015331:Cohort Studies; D003710:Demography; D005260:Female; D005355:Fibrosis; D005544:Forecasting; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006511:Hepatitis B Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000473:pathology / Q000503:physiopathology; D008107:Liver Diseases / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D006511:Hepatitis B Antigens; D000509:alpha-Fetoproteins